Advanced Medical Solutions (AMS) AI Stock Analysis

• Market Cap: £441.19M
• Dividend Yield: 1.27%
• Average Volume (3M): 620.92K
• Price to Earnings (P/E): 61.8
• Beta (1Y): 1.37
• Revenue Growth: 40.66%
• EPS Growth: -55.09%
• Country: UK
• Employees: 1,500
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.01
• Shares Outstanding: 219,243,010
• 10 Day Avg. Volume: 466,227
• 30 Day Avg. Volume: 620,920
• PEG Ratio: 1.69
• Price to Book (P/B): 2.37
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 32.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £245.00
• Price Target Upside: 19.80% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 65 Neutral
• Price Target: 222.00p ▲(8.56%Upside)

Advanced Medical Solutions shows strong growth potential with positive corporate events and solid financial structure. However, challenges in profitability and high valuation temper the overall outlook. Technical indicators offer a neutral perspective, suggesting the stock is currently fairly priced with potential for future gains if operational efficiencies improve.

Positive Factors

Revenue Growth

Revenues increased 41% to £177.5m, boosted by the acquisitions of Peters Surgical and Syntacoll, with organic reported revenue growth of 7%.

Strategic Initiatives

Strategic investment and ongoing integration of Peters are expected to realise deal synergies and start to deliver margin expansion.

Negative Factors

Gross Margin Decline

Adjusted group gross margin declined 250bps to 53.1% due to adverse mix in Woundcare, dilution from lower margins for Syntacoll and Peters, and lower royalty income.

Woundcare Performance

Woundcare saw an 11% decline in revenues with an operating margin of just 6%.

Advanced Medical Solutions Business Overview & Revenue Model

Company Description

Advanced Medical Solutions Group plc, together with its subsidiaries, designs, develops, manufactures, and distributes products for the wound care, surgical, and wound closure markets in the United Kingdom, Germany, France, rest of Europe, the United States, and internationally. It operates in two segments, Surgical and Woundcare. The Surgical segment offers topical tissue adhesives for wound closure and sealing under the LiquiBand brand; sutures and collagen-based products for the surgical and dental markets under the RESORBA brand; collagens; and laparoscopic device used to fix hernia meshes placed inside the body under the LiquiBand Fix8 brand, as well as internal sealants under the Seal-G/Seal-G MIST brand. The Woundcare segment provides wound care platform technologies, which include alginates, foams, films, fibres, hydrogels, antimicrobial dressings, and hydrocolloids, as well as wound care products under the ActivHeal brand. Advanced Medical Solutions Group plc was incorporated in 1991 and is headquartered in Winsford, the United Kingdom.

How the Company Makes Money

AMS makes money primarily through the sale of its medical products to hospitals, clinics, and other healthcare providers. The company generates revenue by developing proprietary technologies and manufacturing products that address specific medical challenges, such as wound care management and surgical efficiency. Key revenue streams include direct sales of wound care dressings, surgical adhesives, and sealants. Additionally, AMS may engage in strategic partnerships with healthcare organizations and distributors to expand its market reach and enhance product adoption. Regulatory approvals and clinical validations play a significant role in the company's ability to market its products effectively, thereby impacting its earnings.

Advanced Medical Solutions Financial Statement Overview

Summary

Advanced Medical Solutions demonstrates strong revenue growth and a solid capital structure. However, declining profitability margins and return on equity suggest potential operational inefficiencies or increased costs. The company's cash flow remains healthy, with a significant increase in operating cash flow, but free cash flow has been constrained by higher capital expenditures.

Income Statement

The company demonstrates a strong gross profit margin of 46.6% in 2024, indicating efficient cost management. However, the net profit margin has decreased from 12.6% in 2023 to 4.0% in 2024, suggesting increased expenses or lower operating efficiency. Revenue growth from 2023 to 2024 shows a significant increase of 40.6%, indicating robust demand for the company's products. EBIT and EBITDA margins have decreased to 5.9% and 16.7% respectively in 2024, highlighting potential operational challenges.

Balance Sheet

The balance sheet reflects a solid equity base with a debt-to-equity ratio of 0.36 in 2024, suggesting moderate leverage and financial stability. The equity ratio remains healthy at 61.9% in 2024, underscoring a strong capital structure. However, the return on equity has declined to 2.9% in 2024 from 6.5% in 2023, indicating reduced profitability relative to shareholder investments.

Cash Flow

Operating cash flow has increased by 35.5% from 2023 to 2024, reflecting improved cash-generating capability. However, free cash flow has decreased due to higher capital expenditures. The operating cash flow to net income ratio is 2.36 in 2024, indicating strong cash flow relative to earnings. Nonetheless, the free cash flow to net income ratio is 1.79, which is robust, although lower than previous years.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	177.52M	126.21M	124.33M	108.60M	86.80M
Gross Profit	82.77M	70.14M	68.62M	56.12M	42.67M
EBITDA	29.68M	31.40M	34.94M	29.45M	17.53M
Net Income	7.09M	15.89M	20.41M	17.48M	8.58M
Balance Sheet
Total Assets	389.00M	289.17M	281.09M	249.51M	238.56M
Cash, Cash Equivalents and Short-Term Investments	17.04M	60.16M	82.26M	72.97M	53.83M
Total Debt	86.56M	9.14M	9.75M	9.86M	11.12M
Total Liabilities	147.48M	44.97M	44.47M	36.83M	36.34M
Stockholders Equity	240.78M	244.20M	236.62M	212.68M	202.21M
Cash Flow
Free Cash Flow	12.67M	2.50M	17.12M	23.95M	15.79M
Operating Cash Flow	16.73M	12.35M	27.08M	30.41M	21.05M
Investing Cash Flow	-68.38M	-20.27M	-12.70M	-6.41M	-27.05M
Financing Cash Flow	9.47M	-13.26M	-5.70M	-4.41M	-5.09M

Advanced Medical Solutions Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 204.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AMS, the sentiment is Negative. The current price of 204.5 is below the 20-day moving average (MA) of 208.22, above the 50-day MA of 203.20, and below the 200-day MA of 204.63, indicating a bearish trend. The MACD of 0.10 indicates Positive momentum. The RSI at 44.25 is Neutral, neither overbought nor oversold. The STOCH value of 19.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:AMS.

Advanced Medical Solutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSTL	82 Outperform	£198.00M	32.15	19.61%	4.07%	10.32%	1.25%
CTEC	71 Outperform	£5.32B	35.82	11.12%	2.10%	3.94%	41.63%
Sector *	70 Outperform	€3.51B	23.95	22.76%	2.41%	32.58%	18.20%
AMS	65 Neutral	£441.19M	61.78	2.93%	1.27%	40.66%	-55.09%
PRTC	63 Neutral	£312.81M	7.95	11.74%	―	38.80%	―
APH	59 Neutral	$355.92M	―	-5.04%	―	-1.02%	67.70%
AGY	53 Neutral	£393.23M	―	-369.20%	―	4.50%	74.32%

Advanced Medical Solutions Corporate Events

Advanced Medical Solutions Announces Total Voting Rights Update

Advanced Medical Solutions Group plc announced its total voting rights as of June 30, 2025, with an issued share capital comprising 219,243,007 ordinary shares. This announcement allows shareholders to calculate their interests in the company according to the FCA’s Disclosure and Transparency Rules, potentially impacting shareholder notifications and interest changes.

The most recent analyst rating on (GB:AMS) stock is a Buy with a £2.45 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.

Advanced Medical Solutions Group Successfully Passes All AGM Resolutions

Advanced Medical Solutions Group plc announced that all resolutions were passed at its Annual General Meeting held in London. The resolutions included financial statements, remuneration reports, auditor remuneration, director elections, and special resolutions on share allotment and pre-emption rights. This successful meeting underscores the company’s stable governance and continued focus on strategic growth, potentially reinforcing stakeholder confidence and supporting its market position in the tissue-healing technology industry.

The most recent analyst rating on (GB:AMS) stock is a Buy with a £2.45 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.

Advanced Medical Solutions Group’s AGM Highlights Governance Enhancements

Advanced Medical Solutions Group plc held its Annual General Meeting on June 30, 2025, where CEO Chris Meredith presented without introducing new material information. The meeting confirmed Juliet Thompson’s appointment to the Board and as Chair of the Audit Committee, enhancing the company’s governance structure. The AGM results will be announced to the London Stock Exchange and posted on the company’s website, reflecting AMS’s commitment to transparency and stakeholder engagement.

The most recent analyst rating on (GB:AMS) stock is a Hold with a £245.00 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.

AMS Appoints Juliet Thompson as Independent Non-Executive Director

Advanced Medical Solutions Group plc has announced the appointment of Juliet Thompson as an Independent Non-Executive Director and Chair of the Audit Committee, effective after the AGM on 30 June. With over 30 years of experience in finance and healthcare, Thompson’s expertise is expected to strengthen AMS’s board, particularly in audit and strategic advisory roles, as the company continues its growth trajectory in the tissue-healing technology sector.

The most recent analyst rating on (GB:AMS) stock is a Buy with a £2.45 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.

Advanced Medical Solutions Releases Annual Report and Announces AGM

Advanced Medical Solutions Group plc has released its Annual Report and Accounts for the year ending December 31, 2024, and announced its Annual General Meeting scheduled for June 30, 2025. The report is accessible on the company’s website, and the AGM will take place in London. This announcement underscores AMS’s commitment to transparency and shareholder engagement, potentially strengthening its market position and stakeholder confidence.

The most recent analyst rating on (GB:AMS) stock is a Buy with a £2.45 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.

Advanced Medical Solutions Announces Change in Voting Rights

Advanced Medical Solutions Group PLC has announced a change in its voting rights structure due to a recent transaction involving Octopus Investments Limited. The transaction resulted in Octopus Investments holding 11.95% of the voting rights, down from a previous 12.99%. This adjustment in voting rights may impact the company’s governance dynamics and reflects ongoing changes in shareholder composition.

The most recent analyst rating on (GB:AMS) stock is a Buy with a £2.45 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.

Advanced Medical Solutions Announces Total Voting Rights Update

Advanced Medical Solutions Group plc announced its total voting rights, with an issued share capital of 219,201,148 ordinary shares as of May 30, 2025. This information is crucial for shareholders to determine their notification obligations under the FCA’s Disclosure and Transparency Rules. The announcement reflects AMS’s commitment to transparency and regulatory compliance, potentially impacting shareholder engagement and market perception.

The most recent analyst rating on (GB:AMS) stock is a Buy with a £2.45 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.

Advanced Medical Solutions Appoints New Joint Corporate Broker

Advanced Medical Solutions Group plc has appointed Joh. Berenberg, Gossler & Co KG as a joint Corporate Broker alongside Investec Bank plc, effective immediately. This strategic move is expected to enhance AMS’s market presence and strengthen its financial advisory capabilities, potentially impacting its operations and industry positioning positively.

The most recent analyst rating on (GB:AMS) stock is a Buy with a £2.45 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.

Advanced Medical Solutions Directors Increase Shareholdings

Advanced Medical Solutions Group plc announced recent share transactions involving its directors and employees. Susan Searle, a Non-Executive Director, and her husband purchased shares, while CEO Chris Meredith and CFO Eddie Johnson engaged in transactions to reinvest in the company’s Share Incentive Plan (SIP) and Employee Share Purchase Plan (ESPP). These transactions reflect the directors’ commitment to the company’s growth and align their interests with those of shareholders. The moves are expected to strengthen their beneficial ownership and demonstrate confidence in the company’s future prospects.

The most recent analyst rating on (GB:AMS) stock is a Buy with a £2.45 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.

Advanced Medical Solutions Announces AGM Delay and Dividend Record Date Change

Advanced Medical Solutions Group plc has announced a delay in its Annual General Meeting (AGM) to 30 June 2025 due to unforeseen changes within its audit team at Deloitte LLP. Consequently, the record date for the proposed final dividend of 1.83p per share has been moved to 20 June 2025, with the dividend payment scheduled for 17 July 2025, pending shareholder approval at the AGM. This adjustment reflects the company’s commitment to maintaining transparency and adapting to operational changes, which may impact shareholder expectations and financial planning.

The most recent analyst rating on (GB:AMS) stock is a Buy with a £2.45 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.

Advanced Medical Solutions Grants New Share Options to Directors

Advanced Medical Solutions Group plc has announced the granting of new nil-cost share options to its directors under the Long Term Incentive Plan (LTIP), based on performance criteria such as Earnings Per Share and Total Shareholder Return. This move is part of the company’s strategy to align management incentives with shareholder interests, potentially impacting its market positioning and stakeholder confidence.

Advanced Medical Solutions Announces Share Capital Details

Advanced Medical Solutions Group plc announced its total issued share capital as of April 30, 2025, which comprises 218,107,619 ordinary shares with voting rights. This information is essential for shareholders to determine their notification obligations under the FCA’s Disclosure and Transparency Rules, potentially impacting shareholder engagement and compliance activities.

AMS Confirms Montagu’s Decision Against Acquisition Offer

Advanced Medical Solutions Group plc announced that Montagu Private Equity LLP has decided not to make an offer for the company, as confirmed by Montagu’s adherence to Rule 2.8 of the City Code on Takeovers and Mergers. The AMS Board expressed satisfaction with the company’s performance and remains confident in its growth strategy, which is expected to drive value creation for shareholders.